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Abstract. Lung cancer is the leading cause for cancer related deaths.
As such, there is an urgent need for a streamlined process that can allow
radiologists to provide diagnosis with greater efficiency and accuracy.
A powerful tool to do this is radiomics: a high-dimension imaging fea-
ture set. In this study, we take the idea of radiomics one step further
by introducing the concept of discovery radiomics for lung cancer pre-
diction using CT imaging data. In this study, we realize these custom
radiomic sequencers as deep convolutional sequencers using a deep con-
volutional neural network learning architecture. To illustrate the prog-
nostic power and effectiveness of the radiomic sequences produced by the
discovered sequencer, we perform cancer prediction between malignant
and benign lesions from 97 patients using the pathologically-proven di-
agnostic data from the LIDC-IDRI dataset. Using the clinically provided
pathologically-proven data as ground truth, the proposed framework pro-
vided an average accuracy of 77.52% via 10-fold cross-validation with a
sensitivity of 79.06% and specificity of 76.11%, surpassing the state-of-
the art method.
Keywords: Radiomics, discovery radiomics, deep convolutional neural
network, lung nodules
1 Introduction
According to the American Cancer Society [1], lung cancer is the second most
diagnosed form of cancer in the United States, second only to prostate cancer
in males and breast cancer in females. Furthermore, lung cancer remains the
leading cause of cancer-related deaths in the United States, accounting for ap-
proximately 27% of all cancer-related deaths. A similar report by the Canadian
Cancer Society [2] estimates the number of new cases of lung cancer to be the
highest of all cancers in Canada, and it is also the leading cause of cancer-related
deaths in Canada, accounting for approximately 26% of all cancer-related deaths.
Early screening and diagnosis of lung cancer at a more treatable stage of the
disease can play a pivotal role in improving the survival rates for such patients.
One of the biggest emerging areas in recent years related to quantitative can-
cer screening and diagnosis is radiomics [3,4], which involves the high-throughput
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extraction and analysis of a large number of imaging-based features for quanti-
tative characterization and analysis of tumour phenotype. The use of radiomics-
driven approaches allow for a more objective and quantitative evaluation and
diagnosis of cancer, which can significantly reduce inter-observer and intra-
observer variability and improve diagnostic accuracy and efficiency compared
to current qualitative cancer assessment strategies. In a comprehensive study by
Aerts et. al. [5] involving more than 1000 patients across seven datasets, it was
shown that radiomics can be used to obtain phenotype differences between tu-
mours that can have clinical significance and prognostic value. The idea behind
the success of radiomics as revealed by radio-genomics is the radiomic sequences
being generated were able to capture quantitative features that define intra-
tumour heterogeneity, which is directly related to the underlying gene-expression
patterns [5]. Other radiomics-driven approaches have been investigated for lung
cancer prediction [6,7,8]. For example, Anirudh et. al. [6] used automated weakly
labeled data with 3D CNNs to classify lung nodules for SPIE-LUNGx challenge.
In [9], Orozco et. al., used a radiomic sequence consisting of wavelet features and
illustrated its effectiveness on a smaller sub-set of CT images from the LIDC-
IDRI dataset. Shen et. al. [7] introduced a convolutional radiomic sequencer,
based on multi-crop windows around the lung nodules effectively and later ex-
tends the framework [8] to rate the suspiciousness of nodules. One important
thing to note here is that, all of the above mentioned literature explored the
radiologist driven nodule ratings for predicting the malignant of nodules.
In this study, we use the concept of discovery radiomics for lung cancer pre-
diction, where we discover custom radiomic sequencers tailored for lung cancer
characterization and prediction using pathologically-proven diagnostic dataset.
To realize the concept of discovery radiomics for lung cancer prediction in this
study, we introduce a deep convolutional radiomic sequencer that is discovered
using a deep convolutional neural network architecture based on CT imaging
data and pathologically-proven diagnostic data from past patients in a medical
imaging archive. This methodology of using a more challenging pathologically-
proven diagnostic data as ground truth distinguishes this study from the above
mentioned literature that are based only on radiologist provide malignancy
scores. In recent past, only two studies were proposed [10,11], which also explores
the pathologically-proven dataset from LIDC-IDRI dataset for predicting lung
nodule malignancy. In [11], the authors proposed an autoencoder based unsu-
pervised approach for predicting malignancy of the lung nodules. More recently,
Shen et. al [10] proposed a method using CNN incorporated with multiple in-
stance learning for classifying the pathologically-proven diagnostic data. In [10],
the authors performed knowledge (weight) transfer from CNN trained on large
non-diagnostic data to a different CNN for the task for diagnostic malignancy
prediction. The authors compared different methodologies and prove that their
method is the current state-of-the art in this domain. In this study, we surpass
the state-of-the art results stated in [10] which proves the effectiveness for the
proposed discovery radiomics approach.
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Fig. 1. Overview of the proposed discovery radiomics framework for CT lung cancer
prediction. A custom radiomic sequencer is discovered directly using the wealth of lung
CT data, hand annotations by the radiologist, and diagnostic results available from
the imaging archive. The discovered radiomic sequencer can then be used to generate
custom radiomic sequences for new patients using their lung CT data.
The main contributions of this study can be summarized as follows: (i) An
effective malignancy prediction framework can be developed with limited patho-
logically proven diagnostic data without any external knowledge or large radiolo-
gist based annotated dataset. (ii) We provide experimental evidence that the pro-
posed discovery radiomics framework is more effective in predicting pathologically-
proven malignancy than the state-of-the art method [10].
2 Methodology
This section presents the methodology used in this study in detail. The various
steps involved in the proposed discovery radiomics framework for lung cancer
prediction is shown in the Fig. 1. First, using the wealth of CT imaging data,
radiologist annotations, and pathologically-proven diagnostic results for past pa-
tients available in a medical imaging archive, a custom radiomic sequencer is
discovered for generating radiomic sequences composed of abstract, quantitative
imaging-based features that characterize tumour phenotype. Once we obtain the
discovered radiomic sequencer, we can apply this sequencer to any new patient
case to extract radiomic sequences tailored for lung cancer characterization and
prediction.
2.1 Patient Data Collection
For learning the custom radiomic sequencer in the proposed discovery radiomics
framework, a set of lung CT images, radiologist annotations, and pathologically-
proven diagnostic results from past patients is needed. In this study, we use a
subset of LIDC-IDRI [12] dataset. Seven different academic and eight medical
imaging companies collaborated to build the LIDC-IDRI database, which con-
sists of data for 1,010 patients, each of which contains clinical helical thoracic CT
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scans and associated data of two-phase annotation process performed by four
experienced thoracic radiologists. For annotating the nodules in the lung CT
scans, a two phase annotation process was finalized for obtaining the interpreta-
tion from up to four different radiologists for a single CT scan. The radiologists
marked each identified lesion as either a nodule of size >= 3mm, < 3mm or
non-nodule >= 3mm. The database contains a total of 7,371 lesions marked
as nodule by at least one radiologists with 2,699 of them marked >= 3mm.
We selected a subset of the LIDC-IDRI of 97 patient cases, for which definite
pathologically-proven diagnostic results were available. The diagnostic results
were obtained at two levels: i) patient level and ii) nodule level. At each level,
the lesions in lung were marked as either: 0 - Unknown (no data),1 - Benign,
2 - Primary malignancy or 3 - Metastatic lesion with extra-thoracic primary
malignancy.
These ratings were obtained by using either biopsy, surgical resection, pro-
gression or review of radiological images to show two years of stable nodule size.
In this study, we take the lesions marked >= 3mm for only the cases with rat-
ings of 1, 2 or 3 and classifying the ratings 2 and 3 as malignant and rating 1 as
benign. This resulted in 69 patient cases for malignant and 28 patient cases for
benign lesions, with a total of 608 benign lesions and 3,698 malignant lesions. It
is important to note here that lesions >= 3mm were considered to facilitate for
a fair comparison with other state-of-the art methods [10,11].
2.2 Data Augmentation
For building an effective radiomics sequencer that can well represent and charac-
terize different types of the lung lesions and have a prognosis efficacy similar to
the pathologically-proven diagnosis level results, there is a need of larger datasets
for the radiomic sequencer discovery process. Therefore, to further enrich our
dataset, we take each lesion candidate associated with pathologically-proven di-
agnostic dataset and perform spatial deformation using rotations. Using this, we
ended with a total of 42,340 lesion candidates to be used for radiomic sequencer
discovery. More specifically, each lesion for the malignant cases is rotated by 45
degrees in total eight different variations for the particular lesion to get 29,956
malignant lesions. As the initial number of cases marked with benign were very
less and it is ideal to have a balanced dataset for the radiomic sequencer discov-
ery process, we rotated each benign lesion by 10 degrees from 0 to 360 degrees
resulting in 22,384 benign lesions for creating near equal lesion candidate ratio
for both the categories.
Table 1. Summary of number of receptive fields and receptive field size at each con-
volutional sequencing layer.
Sequencing Layer Number of Receptive Fields Receptive Field Size
1 20 3× 3
2 50 3× 3
3 500 3× 3
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Fig. 2. Architecture of the deep convolutional radiomic sequencer consists of 3 con-
volutional sequencing layers and 2 max pooling sequencing layers, which outputs a
radiomic sequence with 500 abstract imaging-based features.
2.3 Radiomic Sequencer
Given the CT imaging data, radiologist annotations, and pathologically-proven
diagnostic results for past patients, the next step is to discover a custom ra-
diomic sequencer for generating radiomic sequences tailored for lung cancer pre-
diction. To realize the concept of discovery radiomics for lung cancer prediction
in this study, we take inspiration from deep network architectures, which has
been shown to be effective for medical image analysis [13,7] and introduce a
deep convolutional radiomic sequencer that is discovered using a deep convolu-
tional neural network architecture. The architecture of the deep convolutional
radiomic sequencer is shown in Fig. 2. The proposed radiomic sequencer has
3 convolutional sequencing layers; the number of receptive fields and receptive
field size used in each convolutional sequencing layer is specified in Table 1.
In between each pair of convolutional sequencing layers there is a max-pooling
sequencing layer for improving translational tolerance. The final output of the
deep convolutional radiomic sequencer is a radiomic sequence with 500 abstract
imaging-based features.
Radiomic Sequencer Discovery To discover the aforementioned deep convo-
lutional radiomic sequencer, we construct a deep convolutional neural network
architecture for the radiomic sequencer discovery process, where the radiomic se-
quencer is directly embedded in the sequencer discovery architecture and learned
based on the available CT imaging data, radiologist annotations, and diagnos-
tic results from past patients. In the radiomic sequencer discovery architecture,
a fully-connected layer, a rectified linear unit layer, and a loss layer are aug-
mented at the end of the radiomic sequencer to be discovered for the learning
process. The receptive fields in the convolutional sequencing layers of the ra-
diomic sequencer along with the fully-connected layer in the sequencer discovery
architecture are learned in a supervised manner based on the input CT imaging
data. This process allows us to learn specialized receptive fields in the custom
radiomic sequencer that better characterize the unique tumour traits captured in
the CT imaging data in an abstract fashion beyond that can be captured using
pre-defined, hand-engineered features in current radiomics-driven approaches. A
softmax loss function is used in the loss layer of the sequencer discovery process,
and stochastic gradient descent (SGD) is used for optimization in learning the
radiomic sequencer. Furthemore, a rectified linear unit (ReLU) layer is used to
introduce non-saturating nonlinearity into the sequencer. We initialize the learn-
ing process with a learning rate of 0.001 and complete the learning process in
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60 epochs using a batch size of 100. The momentum is fixed to 0.9 with weight
decay parameters set to 0.0005 through-out the learning process.
Radiomic Sequence Generation After the custom deep convolutional ra-
diomic sequencer has been discovered by the radiomic sequencer discovery pro-
cess, it can then be used for generating radiomic sequences. As shown in Fig. 2,
for a new patient case, we take the CT imaging data pertaining to the patient
and feed it into radiomic sequencer to obtain a final custom radiomic sequence
with 500 abstract imaging-based features.
3 Experimental Results
This section provides details about the experimental setup and obtained results
that are used to evaluate the efficacy of the proposed discovery radiomics frame-
work for the purpose of classifying lung lesions as either malignant or benign
based on CT imaging data and pathologically-proven diagnostic data. The first
subsection explains the experimental setup including the performance metrics,
and the later subsections present the results obtained using the experimental
setup for the task of lesion classification.
Table 2. Comparison of Patient-Level Classification Results Obtained using Discov-
ered Radiomics Sequencers (DRS), CNN Multiple Instance Learning (CNN-MIL) [10]
and Deep Autoencoding Radiomic Sequencers (DARS) [11]. The best results are high-
lighted in bold.
DRS CNN-MIL [10] DARS [11]
Sensitivity (%) 79.06 – 83.14
Specificity (%) 76.11 – 20.18
Accuracy (%) 77.52 70.69 75.01
To create the input data for discovering the radiomics sequencer in the pro-
posed discovery radiomics framework, we first extract the lung CT scans from
the LIDC-IDRI dataset [12] for particular patients which have diagnostic data
associated with their cases. Based on the diagnostic result, we were able to
get lung CT scan images for 97 patients and divided them into two groups: i)
malignant, and ii) benign. From each individual scan, we extracted the lesion
based on the provided radiologist annotations of the lesion in the particular CT
scan image by up to four radiologists for each image which was later verified
by pathological data. To mitigate the inter-observability differences, we include
all of the annotations provided by each radiologist. As stated earlier, after the
data augmentation process, the enriched dataset contains 42,340 lung lesions
composed of 29,956 of malignant lesions and 22,384 benign lesions. To be con-
sistent with the past approaches in this domain, for evaluation purposes, we
divided the dataset into two parts: 90% of the dataset is used for discovering a
custom radiomic sequencer, and 10% of the dataset is used for testing classifica-
tion performance using the discovered radiomic sequencer. We further divide the
90% into two parts: 80% for training and 10% as a validation set for validating
the training process. A binary decision tree classifier is used for evaluating the
efficacy of utilizing the discovered radiomic sequencers for classifying between
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benign and malignant tumours. Performance is quantitatively determined via
sensitivity, specificity and accuracy metrics.
3.1 Results and Analysis
The detailed results for the experiment are presented in Table 2. Through the
10 fold cross validation using the same setup we obtain an average accuracy
of 77.52% with 79.06% sensitivity and 76.11% specificity using the discovered
radiomic sequencer. Furthermore, we also present a comparison of the results ob-
tained using the discovered radiomic sequencer (DRS) along with the results ob-
tained using Deep Autoencoding Radiomic Sequencers (DARS) [11] and the cur-
rent state-of-the art CNN Multiple Instance Learning approach (CNN-MIL) [10]
(see Table 2). It is important to note here that while other past works in the area
of lung nodule classification have reported higher accuracy for a similar experi-
mental setup and dataset [7,8,14], these methods are based on ratings provided
by radiologists as ground truth for malignancy, which can affect the reliability
of the experimental results as it introduces additional inter-observer variability
from the radiologists. To have a just comparison with the presented approach, we
perform comparisons with CNN-MIL and DARS as these methods are based on
pathologically-proven lung cancer prediction, which is considered to be the gold
standard for ground truth. This results in a much more difficult but more reli-
able evaluation configuration similar to [10,11]. From Table 2, it is evident that
proposed discovery radiomic sequencers framework attains much better overall
accuracy compared to CNN-MIL [10] and outperforms the DARS [11] method
on both accuracy and sensitivity while producing similar results for sensitivity.
These results show that the proposed radiomics discovery framework has strong
potential for improving diagnostic accuracy for lung cancer prediction.
4 Conclusion
In this study, we presented a discovery radiomics framework designed for patho-
logically proven lung cancer prediction using CT imaging data and diagnostic
data. Since the custom radiomic sequencers are dependent on the data on which
they are learned, the discovered radiomic sequencers produce highly tailor-made
radiomic sequences for the tumour type, in this case lung nodules. Experimental
results show that the discovered radiomic sequencers, when used for patholog-
ically proven lung nodule classification, outperform state-of-the art approach
when evaluated using the LIDC-IDRI diagnostic dataset. As such, the presented
discovery radiomics framework can be a low cost, fast and repeatable way of pro-
ducing quantitative characterizations of tumour phenotype that has the potential
to speed up the screening and diagnosis process while improving consistency and
accuracy.
In terms of future work, an area that is worth investigating is on the use of
discovery radiomics for risk stratification. Furthermore, the discovery radiomics
framework has the potential to be of high clinical impact in the field of tumour
grading and staging analysis.
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